Press releases
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
- Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
- Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
- Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
- Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
- Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
More ▼
Key statistics
On Thursday, Silence Therapeutics PLC (XRP2:STU) closed at 19.10, -23.60% below its 52-week high of 25.00, set on Mar 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.30 |
---|---|
High | 19.30 |
Low | 19.10 |
Bid | 18.60 |
Offer | 21.20 |
Previous close | 19.90 |
Average volume | 0.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 02 2024.
More ▼